CD19‐directed chimeric antigen receptor T‐cell therapy tisagenlecleucel has shown promising results in the treatment of pediatric patients with relapsed/refractory B‐cell precursor acute lymphoblastic leukemia (BCP‐ALL). This evidence concerns the gene CD19 and acute lymphoblastic leukemia.